Simplex Trading
NBIX icon

Simplex Trading’s Neurocrine Biosciences NBIX Stock Holding History

Simplex Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.2K Buy
700
+200
+40% +$26.5K ﹤0.01% 5180
2025
Q4 		$70.9K Sell
500
-4,000
-89% -$579K ﹤0.01% 5329
2025
Q3 		$631K Sell
4,500
-2,000
-31% -$271K ﹤0.01% 3545
2025
Q2 		$816K Buy
6,500
+2,800
+76% +$321K ﹤0.01% 2990
2025
Q1 		$409K Sell
3,700
-4,300
-54% -$545K ﹤0.01% 3611
2024
Q4 		$1.09M Sell
8,000
-19,900
-71% -$2.46M ﹤0.01% 2749
2024
Q3 		$3.21M Sell
27,900
-12,200
-30% -$1.67M ﹤0.01% 1866
2024
Q2 		$5.52M Sell
40,100
-8,800
-18% -$1.21M ﹤0.01% 1377
2024
Q1 		$6.74M Buy
48,900
+28,900
+145% +$3.95M ﹤0.01% 1374
2023
Q4 		$2.63M Buy
20,000
+600
+3% +$69.1K ﹤0.01% 2135
2023
Q3 		$2.18M Sell
19,400
-2,300
-11% -$242K ﹤0.01% 2003
2023
Q2 		$2.05M Buy
21,700
+18,600
+600% +$1.82M ﹤0.01% 1961
2023
Q1 		$313K Sell
3,100
-22,400
-88% -$2.33M ﹤0.01% 3796
2022
Q4 		$3.04M Buy
25,500
+7,800
+44% +$914K ﹤0.01% 1551
2022
Q3 		$1.88M Buy
17,700
+9,600
+119% +$974K ﹤0.01% 2013
2022
Q2 		$789K Sell
8,100
-13,100
-62% -$1.21M ﹤0.01% 2889
2022
Q1 		$1.99M Buy
21,200
+13,100
+162% +$1.11M ﹤0.01% 2125
2021
Q4 		$689K Sell
8,100
-28,900
-78% -$2.66M ﹤0.01% 3385
2021
Q3 		$3.61M Hold
37,000
– – ﹤0.01% 1495
2021
Q2 		$3.6M Buy
37,000
+36,722
+13,209% +$3.52M ﹤0.01% 1493
2021
Q1 		$2.7M Buy
278
+43
+18% +$4.51K ﹤0.01% 1304
2020
Q4 		$2.25M Buy
235
+23
+11% +$2.22K ﹤0.01% 1659
2020
Q3 		$2.04M Buy
212
+19
+10% +$2.2K ﹤0.01% 1511
2020
Q2 		$2.35M Sell
193
-64
-25% -$7.07K ﹤0.01% 1386
2020
Q1 		$2.22M Buy
257
+170
+195% +$16.6K ﹤0.01% 1204
2019
Q4 		$935K Sell
87
-237
-73% -$24.8K ﹤0.01% 2150
2019
Q3 		$2.92M Sell
324
-84
-21% -$7.85K 0.01% 1044
2019
Q2 		$3.44M Buy
408
+40
+11% +$3.28K 0.01% 920
2019
Q1 		$3.24M Sell
368
-295
-44% -$24.7K 0.01% 979
2018
Q4 		$4.73M Buy
663
+414
+166% +$39.7K 0.01% 604
2018
Q3 		$3.06M Buy
249
+100
+67% +$11.3K 0.01% 917
2018
Q2 		$1.46M Sell
149
-158
-51% -$14.1K 0.01% 1413
2018
Q1 		$60K Buy
307
+201
+190% +$17K ﹤0.01% 2260
2017
Q4 		$134K Buy
106
+101
+2,020% +$6.89K 0.01% 1576
2017
Q3 		$2K Sell
5
-188
-97% -$9.92K ﹤0.01% 5110
2017
Q2 		$19K Sell
193
-33
-15% -$1.6K ﹤0.01% 3345
2017
Q1 		$61K Buy
226
+158
+232% +$6.77K ﹤0.01% 2188
2016
Q4 		$17K Sell
68
-216
-76% -$9.78K ﹤0.01% 3184
2016
Q3 		$69K Sell
284
-350
-55% -$17.4K ﹤0.01% 1834
2016
Q2 		$165K Buy
634
+410
+183% +$18.9K 0.01% 1118
2016
Q1 		$95K Buy
224
+36
+19% +$1.43K 0.01% 1403
2015
Q4 		$199K Sell
188
-41
-18% -$2.08K 0.02% 882
2015
Q3 		$92K Buy
229
+36
+19% +$1.74K 0.01% 1477
2015
Q2 		$131K Buy
193
+67
+53% +$2.84K 0.01% 1046
2015
Q1 		$263K Sell
126
-159
-56% -$5.69K 0.03% 589
2014
Q4 		$141K Buy
+285
New +$5.4K 0.02% 751

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's NBIX Position: Q1 2026 in Review

Simplex Trading increased its Neurocrine Biosciences (NBIX) stake by 22% in Q1 2026, buying an estimated $173K and bringing the position to 7,144 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #2563.

Simplex Trading first reported a position in NBIX in Q4 2014 and has held it in 26 quarters since. The position peaked at $2.21M in Q1 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Simplex Trading held 7,144 shares of Neurocrine Biosciences worth $941K as of Q1 2026.
  • Simplex Trading bought 1,307 Neurocrine Biosciences shares in Q1 2026, an estimated $173K.
  • Neurocrine Biosciences made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #2563 holding.
  • Simplex Trading first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 26 quarters since.
  • Simplex Trading's Neurocrine Biosciences position peaked at $2.21M in Q1 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.